Company intelligence / Profile preview

AbraCos Biosciences

Culver City, California, USA

Ownership: Private
Development stage: Other

Overview

AbraCos Biosciences is a biotechnology company within the NantWorks ecosystem that focuses on the development of next-generation nanoparticle albumin-bound (nab) therapeutics. The company leverages its proprietary albumin-based delivery platform to improve the pharmacokinetic profiles and targeting capabilities of both chemotherapeutic agents and corticosteroids. By utilizing the natural transport properties of albumin, AbraCos aims to deliver higher concentrations of active drugs directly to diseased tissues while minimizing systemic toxicities. Its research and development efforts span oncology and inflammatory diseases, building upon the clinical success of the nab-technology platform originally established with Abraxane.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Partnerships

NantPharmaNantKwest

Beyond the preview

Go deeper on AbraCos Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AbraCos Biosciences.

Explore the full profile